As noted, policies for further testing to confirm anti-D, exclude other antibodies, and assess whether the anti-D is passive or immune vary among TS laboratories.
Even though patient A.D. had a negative antibody screen at 28 weeks and her positive antibody screen prior to the C-section with her current pregnancy appears to be anti-D from RhIG administration at 28 weeks, some TS laboratories may set up a full antibody identification panel to confirm the presence of anti-D. Others would proceed straight to a mini-panel of red cells specifically selected to exclude other clinically significant antibodies in the presence of anti-D.
In this case the laboratory's protocol was to set up a mini-panel of six selected red cells (rr, r'r, and r'r cells), along with a positive Ror control and an autocontrol.
